Markus MD - Cyteir Therapeutics CEO President
| CYTDelisted Stock | USD 2.76 0.01 0.36% |
CEO
Markus MD is CEO President of Cyteir Therapeutics
| Age | 63 |
| Phone | 857 285 4140 |
| Web | https://cyteir.com |
Cyteir Therapeutics Management Efficiency
The company has Return on Asset of (0.145) % which means that on every $100 spent on assets, it lost $0.145. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2381) %, meaning that it generated no profit with money invested by stockholders. Cyteir Therapeutics' management efficiency ratios could be used to measure how well Cyteir Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Cyteir Therapeutics has 889 K in debt with debt to equity (D/E) ratio of 0.02, which may show that the company is not taking advantage of profits from borrowing. Cyteir Therapeutics has a current ratio of 19.55, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Cyteir to invest in growth at high rates of return.
Similar Executives
| Found 11 records | CEO Age | ||
| Lynn MD | Lyell Immunopharma | 65 | |
| Richard Cunningham | Anebulo Pharmaceuticals | 53 | |
| Adrian Gottschalk | Foghorn Therapeutics | 48 | |
| David Hung | Nuvation Bio | 63 | |
| Nevan JD | Rezolute | 57 | |
| Paul Hastings | Nkarta Inc | 64 | |
| Steven MD | Sana Biotechnology | 54 | |
| Ronnie MD | Champions Oncology | 58 | |
| Junyuan Wang | Nuvation Bio | 51 | |
| BAO BCh | Eliem Therapeutics | 48 | |
| Andrew MBA | C4 Therapeutics | 53 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 |
Cyteir Therapeutics Leadership Team
Elected by the shareholders, the Cyteir Therapeutics' board of directors comprises two types of representatives: Cyteir Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyteir. The board's role is to monitor Cyteir Therapeutics' management team and ensure that shareholders' interests are well served. Cyteir Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyteir Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adam Esq, G Counsel | ||
| Markus MD, CEO President | ||
| Paul Secrist, Chief Officer | ||
| Gale Cohen, VP HR | ||
| Lisa Hayes, VP Communications | ||
| Joseph Zakrzewski, Independent Chairman | ||
| Timothy Romberger, Independent Director | ||
| Andrew Gengos, Chief Sec | ||
| Kevin Mills, CoFounder | ||
| David Gaiero, CFO Treasurer |
Cyteir Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyteir Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (20.89 M) | |||
| Shares Outstanding | 36 M | |||
| Shares Owned By Insiders | 6.63 % | |||
| Shares Owned By Institutions | 76.83 % | |||
| Number Of Shares Shorted | 319.73 K | |||
| Price To Earning | 0.36 X | |||
| Price To Book | 0.87 X | |||
| Gross Profit | (16.59 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |